Argonaut Manufacturing Services, a contract manufacturing organization (CMO) serving the life science and molecular diagnostics markets, announced today it has entered into a supply agreement with Celsee, Inc. (“Celsee”), an innovator of comprehensive circulating tumor cell (CTC) and single cell preparation & analysis products.
Celsee, Inc. develops, manufactures, and markets integrated comprehensive single-cell analysis solutions that provide an unprecedented combinational ability to accurately identify, analyze and viably retrieve single cells directly from blood and tissue. Celsee’s platforms provide a practical approach to accurately analyze previously undetectable or rare cells to a scale of millions of single cells from an individual sample. The patented approach incorporates the fundamental properties of gravity for the gentle capture and isolation of individual cells from heterogeneous blood and tissue suspensions. Celsee’s comprehensive single-cell analysis platforms offer a practical solution for understanding and monitoring cell-based diseases.
Celsee, Inc., an innovator of platforms for comprehensive single-cell identification, analysis and retrieval, announced today that they have entered a co-commercialization agreement with IncellDx, Inc., a single-cell diagnostic company offering a pioneering technology platform that enables simultaneous cell classification and single-cell analysis of proteomic and genomic biomarkers.
Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary pharmaceutical and diagnostic company, today announced it has entered into a license and supply agreement with Celsee, Inc., an innovator of progressive rare cell capture, characterization and retrieval products in the emerging field of liquid biopsy.